Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00036738 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 27, 2003
Results First Posted : August 22, 2017
Last Update Posted : April 24, 2018
|
Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
George Georges, Fred Hutchinson Cancer Research Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia that has responded to previous treatment with imatinib mesylate, dasatinib, or nilotinib. Giving low doses of chemotherapy, such as fludarabine phosphate, and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine after the transplant may stop this from happening.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Adult Acute Lymphoblastic Leukemia in Remission Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Blastic Phase Childhood Acute Lymphoblastic Leukemia in Remission Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase of Disease Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Disease | Drug: Cyclosporine Drug: Dasatinib Drug: Fludarabine Phosphate Drug: Imatinib Mesylate Drug: Mycophenolate Mofetil Drug: Nilotinib Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Procedure: Peripheral Blood Stem Cell Transplantation Biological: Therapeutic Allogeneic Lymphocytes Radiation: Total-Body Irradiation | Phase 2 |
PRIMARY OBJECTIVES:
I. To determine whether the rate of leukemia relapse can be decreased for patients with chronic myelogenous leukemia in blast crisis (CML-BC) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) responsive to imatinib mesylate (or either dasatinib or nilotinib for patients who have imatinib-resistant disease or who are intolerant of imatinib) followed by nonmyeloablative hematopoietic stem cell transplantation (HSCT) compared to historical controls given high-dose conventional allogeneic HSCT or chemotherapy.
II. To determine whether the rate of transplantation-related mortality (TRM) can be decreased for patients with CML-BC and Ph+ ALL responsive to imatinib mesylate (or dasatinib or nilotinib) followed by nonmyeloablative HSCT compared to historical controls given high-dose conventional allogeneic HSCT or chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate whether donor lymphocyte infusion (DLI) can be safely used in patients with mixed or full donor chimerism as preemptive therapy to eliminate minimal residual disease.
OUTLINE:
INDUCTION THERAPY: Patients continue to receive imatinib mesylate orally (PO), dasatinib PO, or nilotinib PO once or twice daily until day -2 and resume on day 14 or when blood counts recover after peripheral blood stem cell (PBSC) transplantation.
NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine intravenously (IV) on days -4 to -2; and undergo TBI on day 0.
TRANSPLANTATION: Patients undergo allogeneic PBSC transplantation on day 0.
GRAFT-VERSUS-HOST-DISEASE (GVHD) PROPHYLAXIS: Patients receive mycophenolate mofetil (MMF) PO every 12 hours on days 0-27 (related donor recipients) or every 8 hours on days 0-96 with taper on day 40 (unrelated donor recipients). Patients also receive cyclosporine IV or PO every 12 hours on days -3 to 56, followed by taper on days 57-180 (related donor recipients) or on days -3 to 100, followed by taper on days 101-177 (unrelated donor recipients).
DONOR LYMPHOCYTE INFUSION: Patients with persistent disease and no GVHD after stopping GVHD prophylaxis receive donor lymphocyte infusion IV over 30 minutes once every 28 days for 3 doses.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed up periodically for 2 years and then annually thereafter for 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 28 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial |
| Actual Study Start Date : | July 13, 2001 |
| Actual Primary Completion Date : | July 14, 2014 |
| Estimated Study Completion Date : | September 2018 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Chronic myeloid leukemia
MedlinePlus related topics:
Leukemia
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment (allogeneic nonmyeloablative HSCT)
See Detailed Description
|
Drug: Cyclosporine
Given IV or PO
Other Names:
Drug: Dasatinib Given PO
Other Names:
Drug: Fludarabine Phosphate Given IV
Other Names:
Drug: Imatinib Mesylate Given PO
Other Names:
Drug: Mycophenolate Mofetil Given PO
Other Names:
Drug: Nilotinib Given PO
Other Names:
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Undergo nonmyeloablative allogeneic PBSC transplantation
Other Names:
Procedure: Peripheral Blood Stem Cell Transplantation Undergo allogeneic PBSC transplantation
Other Names:
Biological: Therapeutic Allogeneic Lymphocytes Given IV
Other Name: Allogeneic Lymphocytes Radiation: Total-Body Irradiation Undergo TBI
Other Names:
|
Primary Outcome Measures :
- Relapse Free Survival [ Time Frame: Assessed up to 1 year ]Number of patients with relapsed disease within 1 Year post-transplant. Relapse is defined as the detection of > 5% blasts after a documented complete remission.
Secondary Outcome Measures :
- Leukemia-free Survival [ Time Frame: Assessed up to 5 years ]Number of patients surviving in CR up to five years post-transplant.
- Overall Survival [ Time Frame: Assessed up to 5 years ]Number of patients surviving up to five years post-transplant.
- Transplant-related Mortality [ Time Frame: At day 100 ]Number of patients with TRM within 100 days post-transplant.
- Transplant-related Mortality [ Time Frame: At 1 year ]Number of patients with TRM within one year post-transplant.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 70 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients =< 12 years of age must be approved by Fred Hutchinson Cancer Research Center (FHCRC) principal investigator (PI) in advance
- Patients with a history of Ph+ ALL or CML-BC who, after receiving imatinib mesylate, (or either dasatinib or nilotinib) have < 15% blasts on morphologic marrow evaluation; patients with no detectable Ph+ ALL by morphologic or molecular assays (complete remission) will be accepted
- An appropriately human leukocyte antigen (HLA) matched related or unrelated donor must be prospectively identified who will be available to donate filgrastim (G-CSF) mobilized stem cells
-
RELATED DONOR:
- Related donor who is HLA genotypically identical at least at one haplotype and may be genotypically or phenotypically identical at the allele level at HLA-A, -B, -C, -DRB1, and -DQB1;
- Donor must consent to G-CSR administration and leukapheresis;
- Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian)
-
HLA-MATCHED UNRELATED DONOR:
- FHCRC matching allowed will be grades 1.0 to 2.1; unrelated donors who are prospectively matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing
- A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion; donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment; this determination is based on the standard practice of the individual institution; the recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT; if the PRA shows >10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained; the donor should be excluded if any of the cytotoxic cross match assays are positive; for those patients with an HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results
- Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed
- Only G-CSF mobilized PBSC only will be permitted as a HSC source on this protocol
Exclusion Criteria:
- Central nervous system (CNS) involvement with leukemia refractory to intrathecal chemotherapy; prior to HSCT (all patients must receive a diagnostic lumbar puncture (LP) with intrathecal (IT) chemotherapy as per standard practice)
- Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
- Patients with active non-hematologic malignancies (except non-melanoma skin cancers); this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
- Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a > 20% risk of disease recurrence; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
- Females who are pregnant or breastfeeding
- Patients who are human immunodeficiency virus (HIV)-positive
- Patients with poorly controlled hypertension despite multiple antihypertensives
- Adults: Karnofsky score < 60
- Pediatrics: Lansky play-performance score < 40
- Patients with cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
- Diffusing capacity of the lungs for carbon monoxide (DLCO) < 30%
- Total lung capacity (TLC) < 30%
- Forced expiratory volume in one second (FEV1) < 30% and/or receiving supplementary continuous oxygen; the FHCRC PI of the study must approve enrollment of all patients with pulmonary nodules
- Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension; patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, or symptomatic biliary disease
- Creatinine levels more than 2.2 X's the upper limit of normal (ULN) at the laboratory where the analysis was performed
- Patients with active bacterial or fungal infections unresponsive to medical therapy
- For patients receiving dasatinib or nilotinib, baseline corrected QT interval (QTc) (Fridericia's method) prolongation greater than 500 msec
-
RELATED DONORS:
- Identical twin
- Infection with HIV
- Inability to achieve adequate venous access
- Known allergy to G-CSF
- Current serious system illness
- Bone marrow (BM) donors
-
HLA-MATCHED UNRELATED DONORS:
- BM donors
- Donors who are HIV-positive and/or, medical conditions that would result in increased risk for G-CSF mobilization and harvest of PBSC
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00036738
Locations
| United States, Colorado | |
| Presbyterian - Saint Lukes Medical Center - Health One | |
| Denver, Colorado, United States, 80218 | |
| United States, Washington | |
| VA Puget Sound Health Care System | |
| Seattle, Washington, United States, 98101 | |
| Fred Hutch/University of Washington Cancer Consortium | |
| Seattle, Washington, United States, 98109 | |
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | George Georges | Fred Hutch/University of Washington Cancer Consortium |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | George Georges, Principal Investigator, Fred Hutchinson Cancer Research Center |
| ClinicalTrials.gov Identifier: | NCT00036738 History of Changes |
| Other Study ID Numbers: |
1581.00 NCI-2010-00131 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 1581.00 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) P01CA078902 ( U.S. NIH Grant/Contract ) P30CA015704 ( U.S. NIH Grant/Contract ) |
| First Posted: | January 27, 2003 Key Record Dates |
| Results First Posted: | August 22, 2017 |
| Last Update Posted: | April 24, 2018 |
| Last Verified: | March 2018 |
Additional relevant MeSH terms:
|
Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Blast Crisis Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases |
Cell Transformation, Neoplastic Carcinogenesis Neoplastic Processes Pathologic Processes Fludarabine Fludarabine phosphate Imatinib Mesylate Mycophenolic Acid Dasatinib Cyclosporins Cyclosporine Vidarabine Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites |